Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses
Journal of Virology 81(22): 12102-12110
Article 2007 English
Authors
ZW
Zoe Waibler
MA
Martina Anzaghe
HL
Holger Ludwig
Abstract
1 min read
Modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia virus strain undergoing clinical evaluation as a replication-deficient vaccine vector against various infections and tumor diseases. To analyze the basis of its high immunogenicity, we investigated the mechanism of how MVA induces type I interferon (IFN) responses. MVA stimulation of bone marrow-derived dendritic cells (DC) showed that plasmacytoid DC were main alpha IFN (IFN-α) producers that were triggered independently of productive infection, viral replication, or intermediate and late viral gene expression. Increased IFN-α levels were induced upon treatment with mildly UV-irradiated MVA, suggesting that a virus-encoded immune modulator(s) interfered with the host cytokine response. Mice devoid of Toll-like receptor 9 (TLR9), the receptor for double-stranded DNA, mounted normal IFN-α responses upon MVA treatment. Furthermore, mice devoid of the adaptors of TLR signaling MyD88 and TRIF and mice deficient in protein kinase R (PKR) showed IFN-α responses that were only slightly reduced compared to those of wild-type mice. MVA-induced IFN-α responses were critically dependent on autocrine/paracrine triggering of the IFN-α/β receptor and were independent of IFN-β, thus involving “one-half” of a positive-feedback loop. In conclusion, MVA-mediated type I IFN secretion was primarily triggered by non-TLR molecules, was independent of virus propagation, and critically involved IFN feedback stimulation. These data provide the basis to further improve MVA as a vaccine vector.
Andrea Schuessler, Anneke Funk, Helen M. Lazear, Daphne Cooper, Shessy Torres, Stéphane Daffis, Babal K. Jha, Yutaro Kumagai, Osamu Takeuchi, Paul J. Hertzog, Robert H. Silverman, Akira Shizuo, David J. Barton, Michael Diamond, Alexander A. Khromykh
Discussion(0)
No comments yet. Be the first to comment.